NAD+ and Longevity Peptides — VialBase Guides

Aging at the cellular level converges on a set of interconnected processes: NAD+ depletion, mitochondrial dysfunction, telomere shortening, and impaired DNA repair. Longevity peptides target these processes — some by restoring NAD+-dependent signaling, some by protecting mitochondrial function directly, and some by engaging epigenetic regulation of telomere maintenance.

NAD+ and the Biology of Aging

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every living cell, central to:

• Energy metabolism: NAD+ accepts electrons in glycolysis and the Krebs cycle, feeding the electron transport chain
• Sirtuin activation: NAD+-dependent deacylases (SIRT1–7) regulate chromatin structure, mitochondrial biogenesis, inflammation, and stress responses
• PARP activity: Poly-ADP-ribose polymerases consume NAD+ during DNA repair
• CD38/cADPR signaling: NAD+ is a precursor to cyclic ADP-ribose, involved in calcium signaling

NAD+ levels decline approximately 50% between young adulthood and old age. The causes are multifactorial: increased PARP consumption (more DNA damage with age), increased CD38 activity (CD38 rises with inflammatory aging), and reduced biosynthetic capacity.

This decline has downstream consequences for every NAD+-dependent process — sirtuins slow, DNA repair falters, mitochondria become less efficient, and metabolic flexibility decreases.

Mitochondrial-Derived Peptides

Mitochondria were long thought to encode only 13 proteins. The discovery that the mitochondrial genome also encodes functional peptides — including MOTS-c and Humanin — was a paradigm shift.

MOTS-c

MOTS-c (Mitochondrial ORF of the 12S rRNA type-c) is a 16-amino acid peptide encoded within the 12S rRNA sequence of mitochondrial DNA. Its expression is regulated by cellular metabolic state — it is released from mitochondria under stress and acts as a mitokine, signaling metabolic status to other cells and tissues.

Mechanisms:

• Activates AMPK, a master regulator of cellular energy homeostasis
• Enhances insulin sensitivity and glucose uptake in skeletal muscle
• Reduces fat accumulation and improves metabolic flexibility
• Anti-inflammatory via NF-κB suppression
• Promotes physical performance in animal models; shown to increase exercise endurance

Evidence: Primarily animal studies. MOTS-c declines with age in humans. Exogenous MOTS-c administration in aged mice restores insulin sensitivity, reduces adiposity, and increases lifespan in some models. Human clinical data is early but promising.

Humanin

Humanin is a 21-amino acid peptide also encoded in the 12S rRNA region. It was originally identified in a screen for factors that protect against Alzheimer’s disease-related neurodegeneration.

Mechanisms:

• Anti-apoptotic: inhibits BAX-mediated apoptosis and cytochrome c release
• Neuroprotective: attenuates beta-amyloid toxicity in neurons
• Metabolic: improves insulin sensitivity (similar to MOTS-c)
• Cardiovascular: cardioprotective in ischemia-reperfusion models

Humanin levels decline with age and are lower in individuals with Alzheimer’s disease and metabolic syndrome. Like MOTS-c, most robust evidence is preclinical.

SS-31 (Elamipretide)

SS-31 is a synthetic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) designed by Hazel Szeto and Peter Schiller to target mitochondrial cardiolipin. Unlike MOTS-c and Humanin, it does not have a natural sequence origin — it was engineered.

Mechanism:

• Concentrates in the inner mitochondrial membrane via electrostatic interaction with cardiolipin
• Stabilizes cardiolipin structure, which is essential for cristae architecture and electron transport chain assembly
• Reduces reactive oxygen species production at Complex I and III
• Restores ATP synthase dimerization and efficiency

SS-31 has advanced into human clinical trials for heart failure with preserved ejection fraction (HFpEF) and Barth syndrome (a rare cardiolipin mutation disorder). Phase II trial data showed improved cardiac function and reduced mitochondrial dysfunction. It is the longevity-class peptide with the most advanced human clinical data.

Epithalon and Telomerase Activation

Epithalon (also spelled Epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Vladimir Khavinson’s group at the Institute of Gerontology in St. Petersburg. It is a synthetic analog of Epithalamin, a peptide isolated from the pineal gland.

Mechanisms:

• Upregulates hTERT expression, increasing telomerase activity
• Has been shown to lengthen telomeres in cell culture and in human lymphocytes
• Modulates circadian rhythm via pineal gland interactions
• Normalizes evening cortisol and melatonin secretion in aged individuals
• Antioxidant effects: reduces lipid peroxidation markers

Evidence:

• Multiple Khavinson group studies in humans show telomere lengthening after Epithalon courses
• Animal studies show extended lifespan in rats and mice (up to 33% in some protocols)
• Human studies (primarily Russian literature) show reduced cancer incidence and mortality in elderly patients over 6–12 year follow-up
• Evidence quality limitations: most studies from a single research group; limited independent replication in Western literature

Longevity Peptide Comparison

Practical Considerations

Combining approaches: NAD+ precursors (NMN, NR) are not peptides but are commonly stacked with longevity peptides in research contexts because they address a different layer of the same biology. NAD+ precursors restore substrate availability for sirtuins; peptides like MOTS-c activate downstream effectors.

Epithalon course structure: Research protocols typically involve short courses (10–20 days of daily administration) repeated 1–2 times per year, rather than continuous daily dosing. The rationale is biological priming — inducing telomerase activity without persistent saturation.

SS-31 practicalities: The compound is more expensive and less widely available than other research peptides due to the complexity of its synthesis (it contains non-natural D-amino acids). Clinical trial formulations are intravenous; research use is typically subcutaneous.

Evidence expectations: The longevity peptide space has a high ratio of compelling preclinical data to confirmed human efficacy. MOTS-c and Humanin are highly interesting biologically but should be understood as early-stage research compounds. SS-31 and Epithalon have more advanced evidence, though even their human data is limited by conventional standards.

This content is for educational purposes only and does not constitute medical advice.